A growing coalition of cardiologists, neurologists, and addiction specialists now argues that framing semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) as weight-loss drugs is incomplete and potentially misleading to physicians, patients, and insurers. The billion-dollar narrative built around these medications has focused almost entirely on body weight, but emerging research suggests their real power lies in multiple biological effects that have nothing to do with fat reduction .

What Does the Cardiovascular Evidence Actually Show?

The most direct challenge to the weight-loss narrative came from a landmark trial called SELECT, which enrolled more than 17,600 adults across 45 countries with established cardiovascular disease and overweight or obesity but without type 2 diabetes. Participants were tracked for an average of 34 months, and the findings, published in the New England Journal of Medicine in November 2023, were striking .

Those taking semaglutide experienced a 20% reduction in the composite outcome of nonfatal heart attack, nonfatal stroke, and cardiovascular death compared with placebo. But here's the critical part: a subsequent analysis found that the cardiovascular benefit was not proportional to weight loss. Patients who lost relatively little weight still experienced significant cardiac protection, a finding that strongly implied a mechanism beyond simple fat reduction .

"The data suggested GLP-1 drugs act through pleiotropic mechanisms, meaning they produce multiple biological effects simultaneously, most of which have nothing to do with adipose tissue reduction," said Dr. Michael Lincoff, the cardiologist at Cleveland Clinic who led the SELECT trial.

Dr. Michael Lincoff, Cardiologist at Cleveland Clinic

Are These Drugs Protecting the Brain and Reducing Addiction Cravings?

Cardiologists are not the only specialists paying close attention. Neurologists and addiction medicine physicians have begun accumulating observational data suggesting that GLP-1 receptor agonists substantially reduce cravings for alcohol, nicotine, and opioids, effects that have no plausible weight-loss explanation .

A 2023 retrospective study published in the Addiction journal, using electronic health records from more than 83,000 patients with alcohol use disorder, found that those prescribed semaglutide had a statistically significant reduction in alcohol-related hospitalizations compared with matched controls who were prescribed other diabetes medications. The study, conducted by researchers at the University of Southern California, was observational and could not establish causation, but it aligned with pre-clinical data showing that GLP-1 receptors are expressed in reward-circuit regions of the brain, including the nucleus accumbens and ventral tegmental area .

Separately, a large Danish registry study published in early 2024 in Alzheimer's and Dementia found that patients with type 2 diabetes who were prescribed GLP-1 drugs had a lower incidence of Alzheimer's disease diagnosis over a six-year follow-up compared with patients on other glucose-lowering therapies. The hazard ratio was approximately 0.47, meaning the risk was cut roughly in half. The Alzheimer's Association flagged the finding as a priority area for prospective clinical investigation .

How Has the Weight-Loss Label Complicated Access to These Medications?

The commercial and regulatory categorization of GLP-1 drugs primarily as obesity medications has created a significant coverage problem. Medicare, the U.S. federal health insurance program for adults 65 and older, was barred for decades from covering drugs specifically indicated for weight loss under the 1988 Omnibus Budget Reconciliation Act. That restriction meant that even after the FDA approved Wegovy for chronic weight management in 2021, Medicare could not cover it for that indication alone .

Congress addressed part of that gap through the Treat and Reduce Obesity Act provisions incorporated into the Inflation Reduction Act's downstream rulemaking, and the Centers for Medicare and Medicaid Services finalized a rule in early 2025 allowing Medicare Part D plans to cover anti-obesity medications. However, the coverage pathway remained administratively complex, and many plans imposed prior authorization requirements that independent pharmacists told patient advocacy groups were difficult to navigate .

The FDA did expand Wegovy's labeling in March 2024 to include cardiovascular risk reduction in adults with obesity or overweight and established heart disease, a move that broadened the coverage rationale without requiring a separate drug approval. Health policy analysts at the Brookings Institution noted at the time that the label expansion effectively unlocked a new payer pathway, potentially reaching millions of Medicare beneficiaries who had been previously excluded .

What Are the Current Approved Indications and Coverage Status?

• Type 2 Diabetes (Ozempic): FDA-approved and covered by Medicare Part D as of 2025
• Chronic Weight Management (Wegovy): FDA-approved and covered by Medicare Part D as of early 2025
• Cardiovascular Risk Reduction: FDA-approved label expansion in March 2024 and covered under cardiovascular indication
• Alcohol Use Disorder: Not FDA-approved (used off-label) and not covered by Medicare
• Alzheimer's Prevention: Not FDA-approved (trials ongoing) and not covered by Medicare

What Clinical Trials Are Testing These Broader Effects?

Several Phase III clinical trials are now underway specifically designed to test GLP-1 drugs against neurological and addiction endpoints. Novo Nordisk's EVOKE trial is evaluating oral semaglutide in early Alzheimer's disease. A separate NIH-funded trial, ALCOVE, is studying the effect of semaglutide on alcohol use disorder in a randomized, double-blind format. Results from both are expected before 2028 .

The scientific pressure to reconceive GLP-1 receptor agonists as systemic disease-modifying agents rather than weight-loss aids carries significant real-world implications. Drug pricing negotiations, insurance coverage determinations, and prescribing guidelines all flow from how a medication is categorized. If semaglutide is understood primarily as an anti-inflammatory and neuroprotective agent that also reduces body weight, the cost-benefit calculus for insurers and governments changes substantially .

What Should Patients and Doctors Know Right Now?

For patients and physicians navigating the current landscape, the practical reality is that coverage remains tied to approved indications. But the research trajectory suggests that the commercial and regulatory definition of what GLP-1 drugs are, and who should receive them, is likely to look very different within this decade than it does today. The emerging evidence points to a future where these medications are understood as multi-system treatments rather than single-purpose weight-loss tools, potentially opening access pathways for patients with cardiovascular disease, early cognitive decline, or addiction disorders, regardless of their weight status .